Sinovac’s main source of profit is the sale of vaccines to multiple countries.
According to the specific profitability announced by relevant companies, Sinovac Zhongwei Company accounts for a large proportion. On the one hand, this is because the company has obvious advantages in the field of new crown vaccines and has been listed in many countries and regions. license. On the other hand, it is because the company has established cooperative relationships with many countries, thus supplying 2.8 billion doses of vaccines globally. Profit method one: Exporting COVID-19 vaccines
Since confirmed cases of COVID-19 have appeared in many countries, many countries will seek COVID-19 vaccines. Although some countries have adopted completely different vaccination methods, residents in many countries are eager to receive the new crown vaccine. Since it is difficult for some countries to produce and develop COVID-19 vaccines in the first place, Sinovac has become a partner of many countries. Exporting vaccines makes the company more profitable, and gross profits are improving. Profit method two: increase technology research and development
New crown vaccine production technology and research and development technology have never been a simple concept, but require pharmaceutical companies to spend a lot of time and energy. Increasing technology research and development has become the development goal of Sinovac Zhongwei. When the technology for developing new coronavirus vaccines continues to make breakthroughs, the company has particularly obvious technical advantages. Not only can it directly provide COVID-19 vaccines to multiple countries, but it can also conduct technical cooperation with many companies around the world. Over time, the company has become more and more famous around the world. Not only has it been recognized by residents around the world, it has also led to a smooth increase in the company's profits.
In general, Chinese pharmaceutical companies are showing a steady upward trend, especially many vaccine manufacturers led by Sinovac Zhongwei. They not only demonstrate the comprehensive strength of Chinese pharmaceutical companies, but also reflect the continuous improvement of our country's medical technology. What's more, domestic residents are vaccinated against the new crown virus for free, which reduces residents' expenses on vaccination and ensures the safety of people's lives.